What is Bio Protocol?

Bio Protocol is a decentralized science (DeSci) platform designed to transform how biotechnology research is funded, governed, and shared. It enables the formation of BioDAOs, community-led organizations where scientists, patients, and investors pool resources to support biotech projects, particularly in underfunded or specialized areas. The protocol also facilitates the tokenization of intellectual property (IP), allowing research outputs such as data, patents, or tools to be represented as tradable or shareable assets. In addition, it incorporates milestone-based incentives and automated 'BioAgents' to streamline operations and reduce administrative overhead.

What is BIO?

The native token of the protocol is BIO, operating on the Ethereum blockchain. It serves as both a utility and governance token, used to facilitate decision-making, incentivize participation, and provide access to protocol services. Holders can stake BIO to gain governance rights and engage in protocol initiatives. The token has a fixed supply of 3.2 billion, and at the time of this publication, roughly 1.67 billion BIO is currently in circulation.

Risk Statement

Before trading any crypto assets it is important to understand the risks. This overview is a starting point for you to perform your own research prior to investing in a crypto asset.

No securities regulatory authority or regulator in Canada has evaluated or endorsed the Crypto Contracts or any of the crypto assets made available through the platform.

Wealthsimple has performed an assessment of whether BIO can be supported by Wealthsimple's platform, including whether BIO is a security and/or a derivative and is being offered in compliance with securities and derivatives laws.

We evaluated BIO based on publicly available information, including (but not limited to):

• The creation, governance, usage and design of BIO, including the source code, security and roadmap for growth in the developer community and, if applicable, the background of the developer(s) that first created BIO;
• The supply, demand, maturity, utility and liquidity of BIO;
• Material technical risks associated with BIO, including any code defects, security breaches and other threats concerning BIO and its supporting blockchain (such as the susceptibility to hacking and impact of forking), or the practices and protocols that apply to them;
• Legal and regulatory risks associated with BIO, including any pending, potential, or prior civil, regulatory, criminal, or enforcement action relating to the issuance, distribution, or use of BIO; and
• Statements made by regulators or securities regulatory authorities in Canada and other jurisdictions regarding whether BIO, or generally about whether the type of crypto asset, is a security and/or a derivative.

Wealthsimple monitors ongoing developments related to crypto assets available on its platform for significant changes that may affect Wealthsimple's original assessment of those assets, including Wealthsimple's assessment of the application of securities and derivatives laws. Any significant changes relating to BIO may result in changes to this Crypto Asset Statement and/or Wealthsimple's ability to support BIO.

Like all other crypto assets, there are some general risks to investing in BIO. These include short history risk, volatility risk, liquidity risk, demand risk, forking risk, cryptography risk, regulatory risk, concentration risk, electronic trading risk and cyber security risk. Please review the Wealthsimple Crypto Product Risk Disclosure for additional discussion of general risks associated with the crypto assets made available through the platform.

We emphasize that this Crypto Asset Statement is not exhaustive of all risks associated with trading BIO. Investors should perform their own assessment to determine the appropriate level of risk for their personal circumstances.

Wealthsimple is offering Crypto Contracts in reliance on a prospectus exemption contained in the exemptive relief decision Re Wealthsimple Investments Inc. dated December 18, 2023 (the Decision).

The statutory rights of action for damages and rescission in section 130.1 of the Securities Act (Ontario), and, if applicable, similar statutory rights under securities legislation of other jurisdictions of Canada, do not apply in respect of this Crypto Asset Statement to the extent a Crypto Contract is distributed under the prospectus relief in the Decision.

Last Updated: October 2, 2025